These medications attach to specific sites on certain cells ... In late 2023, the FDA approved Zepbound (tirzepatide), a weekly injection, for weight loss in adults. Unlike other weight-loss ...

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

In clinical trials, the most common adverse effect of this treatment was injection site reaction (ISR). This can occur in up to 49% of patients and usually presents as erythema, pruritus ...

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Eli Lilly has reported comprehensive outcomes from the SURMOUNT-1 study of tirzepatide (Zepbound and Mounjaro) for treating ...

Susan McGowan, 58, from Lanarkshire, died from multiple organ failure, septic shock and pancreatitis after taking two low-dose injections ... regulator of adverse reactions to the drugs, known ...

When I lost weight on WW, I devoted all of my time to the program and I was successful. It was when life got hard that the ...

New research shows that weight loss medications can stop the progression of prediabetes. Experts don’t all agree on such a ...

As the city turns a legal blind eye toward harm reduction sites, it’s important to ask ... safer meth use” and “safer IV injection and safer crack/speedball injection” will reduce overdose ...

patients will have to source their own syringes for the injections. The move is an escalation of the battle between Lilly and Novo Nordisk in the fast-growing obesity drugs market, where Zepbound ...

Jaron “Boots” Ennis successfully defended his IBF welterweight title on Saturday night in Philadelphia at the Wells Fargo Arena, but the performance was from what most expected from the 27 ...